Supplements
Reishi: Ganoderma species, extracts, cancer and metabolic claims, and safety limits
On this page
Reishi, also called lingzhi, is a common name for mushrooms in the Ganoderma genus, a group of wood-decaying fungi. Labels often use Ganoderma lucidum broadly even though molecular work distinguishes several species. A common name on a supplement is therefore an incomplete description of its biological identity.[1]
Separate species, tissues and processing
| Form or term | What it describes | Evidence boundary |
|---|---|---|
| Species label | G. lucidum may be used loosely on commercial labels | Species authentication matters when transferring findings[1] |
| Cultivated versus wild | Different sources of mushroom material | The 2018 survey identified many products as cultivated G. lingzhi[1] |
| Fruiting body | The visible woody mushroom, dried or extracted | Its composition differs from other fungal tissues[2] |
| Mycelium product | Cultured fungal threads, sometimes with growth substrate | Submerged culture and substrate-containing products differ[2] |
| Spores or broken spores | Reproductive particles with different processing | Spore-wall treatment does not establish a clinical benefit[2] |
| Water or alcohol extract | Processing recovers different constituent mixtures | An extraction method is not a proven medical indication[2] |
The material behind the label matters
The original Herbal Medicine chapter describes dried fruiting bodies, extracts, cultured mycelia, substrate-containing fungal products and spores as separate preparations. It discusses polysaccharides and triterpenes as chemically different groups recovered from these materials. These are useful product distinctions, not rankings of effectiveness. A percentage of one constituent, a concentrated extract or a broken-spore claim does not by itself show that the marketed preparation reproduces a human trial.[2]
Species mismatch is a concrete quality problem
Loyd and colleagues used DNA methods to examine manufactured reishi products and grow-your-own kits. Most manufactured products in their 2018 sample were identified as G. lingzhi, despite broad G. lucidum labeling; some contained other Ganoderma species. This was a selected commercial sample, not a current market-wide prevalence estimate. It demonstrates why species-specific findings cannot simply be attached to every reishi label. DNA identification also does not measure clinical effectiveness or all contaminants in an extract.[1]
Evidence & uncertainty
A 16-week placebo-controlled trial in 84 people with type 2 diabetes and metabolic syndrome found no significant benefit for its glucose or cardiovascular-risk outcomes. This directly tested clinical markers and provides a firmer boundary than antioxidant or tumor-cell findings in the laboratory.[3]
Selected-source overview · Independent review pendingPublished questions
Does a Ganoderma lucidum label guarantee the exact reishi species?
Selected-source overview · Independent review pending. Read the evidence context.
No. The 2018 DNA survey found broad labeling of genetically distinct Ganoderma species. It demonstrates an identification problem, without estimating today’s entire retail market.[1]
Evidence behind this answer
- Identifying the Mushroom of Immortality: Assessing the Ganoderma Species Composition in Commercial Reishi Products
original product authentication study · 2018
Selected original full-text methods, results and limitations inspected; no independent systematic appraisal · Wood-decay fungi, species complex, cultivation, selected commercial DNA survey and multiple species
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are reishi spores, mycelium and fruiting-body extracts interchangeable?
Selected-source overview · Independent review pending. Read the evidence context.
No. They are different fungal materials and processing categories. A broken-spore or extract label does not establish that the product matches the intervention in a clinical trial.[2]
Evidence behind this answer
- Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom
original scholarly review chapter · 2011
Original indexed chapter excerpts on forms and chemistry inspected; direct full-text open challenge-blocked · Dried bodies, mycelium/culture substrate, spores and extraction methods; polysaccharides versus triterpenes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Has reishi been shown to treat high blood sugar in diabetes?
Selected-source overview · Independent review pending. Read the evidence context.
The 84-person, 16-week trial found no significant glucose benefit from its reishi interventions. It does not support treating diabetes with an unspecified reishi supplement.[3]
Evidence behind this answer
- A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome
randomized controlled trial · 2016
Original publisher abstract and selected indexed original methods/results inspected; retrieved publisher text incomplete; no independent full-text appraisal · 84 randomized, three groups, combined intervention arms, 16 weeks, glucose/cardiovascular null findings and limited power
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does reishi reliably lower cholesterol or blood pressure?
Selected-source overview · Independent review pending. Read the evidence context.
The cardiovascular Cochrane review found no convincing benefit for those outcomes. Its limited comparative data and uncertain estimates do not support a reliable lowering claim.[4]
Evidence behind this answer
- Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors
systematic review · 2015
Original review abstract, methods and conclusions inspected on Cochrane page; underlying trials not independently appraised · Five eligible trials, three usable comparisons, HbA1c interval, lipid/BP nulls, inconsistent post-meal results and study overlap
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does reishi improve cancer survival or replace cancer treatment?
Selected-source overview · Independent review pending. Read the evidence context.
The cancer review found no long-term survival data and insufficient evidence for first-line treatment. Possible adjunctive signals do not establish a cure or replacement therapy.[6]
Evidence behind this answer
- Ganoderma lucidum (Reishi mushroom) for cancer treatment
systematic review · 2016
Original review abstract, methods and conclusions inspected on Cochrane page; underlying trials not independently appraised · Five trials/373 participants, all Chinese, limited methods, adjunctive signals, no survival and no first-line justification
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the reishi fatigue trial prove that it treats insomnia?
Selected-source overview · Independent review pending. Read the evidence context.
No. It studied neurasthenia, fatigue and global symptom ratings with a specific extract. Insomnia treatment in a different population was not established.[7]
Evidence behind this answer
- A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia
randomized controlled trial · 2005
Original indexed abstract and bibliographic record inspected; attempted page open was unavailable or challenge-blocked; full text not independently inspected · 132 randomized, 123 assessable, eight weeks, CGI and fatigue changes with substantial placebo improvement
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does reishi necessarily impair clotting in everyone?
Selected-source overview · Independent review pending. Read the evidence context.
No. One small healthy-volunteer study found no between-group clotting differences. That result also does not establish safety with anticoagulants or every formulation.[8]
Evidence behind this answer
- A prospective, randomized, double-blind, placebo-controlled study of platelet and global hemostatic effects of Ganoderma lucidum in healthy volunteers
randomized controlled trial · 2005
Original indexed abstract and bibliographic record inspected; attempted page open was unavailable or challenge-blocked; full text not independently inspected · 40 healthy volunteers; four-week capsules; coagulation/platelet testing without significant between-group differences
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can rare liver-injury reports establish that every reishi product is dangerous?
Selected-source overview · Independent review pending. Read the evidence context.
No. Some cases had inadequately excluded alternative causes, and incidence is unknown. The reports still limit blanket safety claims for supplements and mixed products.[9]
Evidence behind this answer
- Lingzhi, Reishi
official safety review · 2024
Original indexed LiverTox overview and selected indexed case-assessment passages inspected; direct full-text open challenge-blocked · Generally tolerated; rare acute-injury reports; inadequate exclusion of alternatives and unknown incidence
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The metabolic-syndrome trial found no glucose benefit
The 2016 trial randomized participants to reishi, reishi plus cordyceps, or placebo for 16 weeks. The investigators combined the two intervention groups for their main analysis. Neither HbA1c nor fasting plasma glucose showed a significant treatment benefit, and secondary cardiovascular-risk markers did not improve. The study was smaller than originally planned, so it cannot exclude every small effect. Nevertheless, its tested product and outcomes do not support marketing reishi as an established treatment for diabetes or cardiovascular risk.[3]
The cardiovascular review found uncertain or negative results
Cochrane’s 2015 review identified five trials with 398 participants, but only three studies supplied usable comparative data. The HbA1c estimate was −0.10 percentage points, with a 95% confidence interval from −1.05 to 0.85, spanning benefit and harm. Blood pressure and lipid outcomes did not show convincing improvements. Post-meal glucose measures disagreed within one study. The review includes data associated with the later published 84-person trial, so these sources must not be counted as independent confirmation.[4]
A newer broad synthesis also separates endpoints
A 2025 meta-analysis pooled 17 trials involving 971 participants across healthy, at-risk and chronic-disease populations. It reported a small BMI reduction, averaging 0.43 kg/m², and changes in some other biomarkers. Blood pressure, fasting glucose and lipid profiles did not show significant pooled effects. Mixing populations, durations and preparations creates applicability problems even when a pooled estimate is statistically significant. Its BMI result does not establish sustained weight control, fewer cardiovascular events or longer life.[5]
Cancer-response signals do not establish survival or a cure
The 2016 Cochrane cancer review included five randomized trials and 373 participants, all recruited in China. It described possible adjunctive tumor-response, immune-marker and quality-of-life signals, but primary studies were small and poorly reported. No trial recorded long-term survival. The review did not justify reishi as first-line cancer treatment. Adjunctive tumor response is different from preventing cancer, curing it or extending survival; those claims cannot be established by cell-culture experiments or by the available trials.[6]
A fatigue result does not make reishi a general sleep remedy
Tang and colleagues studied a specific polysaccharide extract in 132 Chinese patients diagnosed with neurasthenia for eight weeks; 123 were assessable at the end. Fatigue and global-severity scores improved more than with placebo. Fatigue ratings fell 28.3% from baseline in the extract group and 20.1% in the placebo group, illustrating that much improvement occurred without active extract. The tested diagnosis and questionnaires do not establish treatment of insomnia, depression or nonspecific tiredness in every healthy adult.[7]
A small normal-clotting study does not settle medicine combinations
Kwok and colleagues randomized 40 healthy volunteers to capsules or placebo for four weeks and monitored platelet and coagulation measures. They found no significant between-group differences, with measurements remaining within normal ranges. This is useful contrary evidence to a blanket claim that every reishi product impairs clotting. It does not resolve bleeding risk with anticoagulants, other extracts, illness or surgery: a small study of healthy people and surrogate tests has a narrower scope than all those settings.[8]
Rare liver reports have unresolved causes
LiverTox’s October 2024 assessment describes generally good tolerability but rare acute liver-injury reports attributed to reishi or related preparations. Some reports did not adequately exclude gallstones, other medicines, other herbal ingredients or contaminants. The evidence therefore does not establish a precise incidence or prove that the mushroom caused every case. Equally, reassuring short trials cannot exclude rare injury or guarantee every powder and beverage. Dark urine or jaundice in a supplement user warrants assessment of the complete exposure history.[9]
What remains unresolved?
The 2025 synthesis combines many small studies and health indices; its authors judged all assessed outcomes to have very low certainty using GRADE. This guide has not independently completed that process. Favorable pooled biomarkers may reflect an actual preparation-specific effect, selective results or differences in trial quality. Replication with authenticated products, predefined clinical outcomes and longer follow-up would be more persuasive than more tests on the same small groups. Safety in pregnancy, childhood and complex treatment combinations is not established by these adult trials.[5]
References
- Identifying the Mushroom of Immortality: Assessing the Ganoderma Species Composition in Commercial Reishi Products
Original product authentication study
Loyd and colleagues · Content/publication date: 2018
Accessed: 2026-10-14 UTC · Selected original full-text methods, results and limitations inspected; no independent systematic appraisal
Cited sections: Wood-decay fungi, species complex, cultivation, selected commercial DNA survey and multiple speciesUses species names as reported in the dated study; no claim that its sampling represents the 2026 market.
- Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom
Original scholarly review chapter
Wachtel-Galor, Yuen, Buswell and Benzie; Herbal Medicine: Biomolecular and Clinical Aspects · Content/publication date: 2011
Accessed: 2026-10-14 UTC · Original indexed chapter excerpts on forms and chemistry inspected; direct full-text open challenge-blocked
Cited sections: Dried bodies, mycelium/culture substrate, spores and extraction methods; polysaccharides versus triterpenesHistorical product/chemistry explanation only; preclinical claims in the chapter are not used as clinical findings.
- A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome
Randomized controlled trial
Klupp and colleagues · Content/publication date: 2016
Accessed: 2026-10-14 UTC · Original publisher abstract and selected indexed original methods/results inspected; retrieved publisher text incomplete; no independent full-text appraisal
Cited sections: 84 randomized, three groups, combined intervention arms, 16 weeks, glucose/cardiovascular null findings and limited powerOverlaps an unpublished study included in the 2015 Cochrane cardiovascular review.
- Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors
Systematic review
Klupp and colleagues; Cochrane · Content/publication date: 2015
Accessed: 2026-10-14 UTC · Original review abstract, methods and conclusions inspected on Cochrane page; underlying trials not independently appraised
Cited sections: Five eligible trials, three usable comparisons, HbA1c interval, lipid/BP nulls, inconsistent post-meal results and study overlapSearch through June 2014; includes the 84-person study later published in 2016.
- The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials
Systematic review meta analysis
Jafari, Mardani, Mirzaei Fashtali and Arghavan · Content/publication date: 2025
Accessed: 2026-10-14 UTC · Selected original full-text methods, results and limitations inspected; no independent systematic appraisal
Cited sections: 17 RCTs/971 participants, heterogeneous populations/products, BMI signal, glucose/lipid/BP nulls and authors’ evidence assessmentThis source reports its own GRADE assessment; no formal grade has been completed for the Atlas guide. Trials overlap earlier reviews.
- Ganoderma lucidum (Reishi mushroom) for cancer treatment
Systematic review
Jin, Ruiz Beguerie, Sze and Chan; Cochrane · Content/publication date: 2016
Accessed: 2026-10-14 UTC · Original review abstract, methods and conclusions inspected on Cochrane page; underlying trials not independently appraised
Cited sections: Five trials/373 participants, all Chinese, limited methods, adjunctive signals, no survival and no first-line justificationSummary gives response ratio 1.27 while abstract gives RR1.50 with interval0.90–2.51 and discordant p-value; inconsistent estimate not repeated. Search updated February2016.
- A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia
Randomized controlled trial
Tang and colleagues · Content/publication date: 2005
Accessed: 2026-10-14 UTC · Original indexed abstract and bibliographic record inspected; attempted page open was unavailable or challenge-blocked; full text not independently inspected
Cited sections: 132 randomized, 123 assessable, eight weeks, CGI and fatigue changes with substantial placebo improvementDiagnosis and specific polysaccharide extract do not support a generic sleep or depression indication.
- A prospective, randomized, double-blind, placebo-controlled study of platelet and global hemostatic effects of Ganoderma lucidum in healthy volunteers
Randomized controlled trial
Kwok, Ng, Li, Lam and Man · Content/publication date: 2005
Accessed: 2026-10-14 UTC · Original indexed abstract and bibliographic record inspected; attempted page open was unavailable or challenge-blocked; full text not independently inspected
Cited sections: 40 healthy volunteers; four-week capsules; coagulation/platelet testing without significant between-group differencesHealthy-volunteer surrogate results do not establish anticoagulant-combination safety.
- Lingzhi, Reishi
Official safety review
NIDDK LiverTox · Content/publication date: 2024
Accessed: 2026-10-14 UTC · Original indexed LiverTox overview and selected indexed case-assessment passages inspected; direct full-text open challenge-blocked
Cited sections: Generally tolerated; rare acute-injury reports; inadequate exclusion of alternatives and unknown incidenceNo estimate of absolute product-specific incidence; case attribution remains qualified. Original content update October5 differs from PubMed indexing/publication chronology.
Scope & review
- Population
- Adults in metabolic, symptom and safety trials; dated Chinese cancer trials and heterogeneous meta-analysis populations
- Exposure or intervention
- Ganoderma species, dried fungal tissue, polysaccharide extracts, cultured mycelia and spore preparations
- Comparison
- Source-specific placebo or standard cancer care; form/species differences and review overlap preserved
- Outcomes
- Glucose/lipid/BP and other biomarkers, cancer response versus survival, fatigue ratings, clotting tests and liver reports
- Timeframe
- Source-specific acute experiments and trials lasting weeks to months; long-term clinical outcomes remain unresolved
- Jurisdiction
- Selected international human research and original reviews; US liver-safety information is identified; product rules differ by jurisdiction
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added a bounded mushroom-supplement explanation; qualified clinical and methods review remains pending.
What this article still leaves open
- Do authenticated preparations improve clinical outcomes rather than biomarkers?
- Does adjunctive reishi change cancer survival in adequately powered trials?
- Which preparations and medicine combinations alter bleeding or liver-injury risk?
- Are fatigue findings replicated in clearly defined contemporary populations?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.